Star Imaging & Path Lab Ltd. IPO Allotment Today – Listing on 18 August

New Delhi, 13 August 2025 – The allotment status for Star Imaging & Path Lab Ltd. IPO is being finalized today, with investors keenly awaiting the results. The company, a prominent diagnostic and healthcare service provider, came up with an SME public issue aimed at strengthening its operations and expanding its network. The listing is scheduled for 18 August 2025 on the BSE SME platform.

IPO Details

• IPO Type: SME Book-Built Issue

• Total Issue Size: ₹69.47 crore

  • Fresh Issue: ₹55.66 crore

  • Offer for Sale: ₹13.80 crore

• Price Band: ₹135 – ₹142 per share

• Lot Size: 1,000 shares (₹1,42,000 minimum investment)

• IPO Dates:

  • Opened: 8 August 2025

  • Closed: 12 August 2025

  • Allotment: 13 August 2025

  • Refunds & Credit: 14 August 2025

  • Listing: 18 August 2025

Subscription Status

The IPO received strong investor response, with particularly high demand from institutional buyers.

This performance reflects solid institutional confidence in the company’s business model and future prospects.

Grey Market Premium (GMP)

The GMP stood at ₹3 per share ahead of allotment, indicating a possible listing price of around ₹145 per share — a modest ~2% premium over the upper IPO price band. Market observers note that this shows a stable but not overly speculative sentiment.

Company Overview

Star Imaging & Path Lab Ltd. is a well-established name in the diagnostic healthcare space, offering:

• Pathology testing

• Radiology imaging

• Preventive health check-ups

• Specialized diagnostic solutions

With state-of-the-art technology and a growing network, the company aims to enhance service capacity and reach more geographies. The IPO proceeds from the fresh issue will primarily be used for:

1. Expansion of diagnostic centers

2. Purchase of advanced medical equipment

3. Working capital requirements

4. General corporate purposes

Market Impact & Retail Investor Take

Given the healthy subscription figures and steady GMP, the stock is expected to witness stable listing gains rather than a speculative spike. For retail investors, the moderate GMP suggests that those allotted shares may see a small premium on listing day, with further movement likely dependent on quarterly performance and sector growth trends.

The diagnostics sector continues to enjoy structural demand in India, driven by rising healthcare awareness, preventive testing, and an increasing preference for organized healthcare service providers.

💡 Investor Note: Those who applied can check allotment status through BSE SME or Kfin Technologies by entering their PAN or application details.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult their financial advisor before making any investment decisions.